Stoke Therapeutics Inc(STOK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:01 PM ET (Korea 10/28 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.37 | Insider Own | 17.1% | Shs Outstand | 62.4M | Perf Week | -1.8% |
| Market Cap | 1.69B | Forward P/E | - | EPS next Y | 1.42% | Insider Trans | -0.43% | Shs Float | 53.5M | Perf Month | 2.47% |
| Enterprise Value | 1.40B | PEG | - | EPS next Q | -0.93 | Inst Own | 113.38% | Short Float | 19.18% | Perf Quarter | -11.36% |
| Income | -0.21B | P/S | 61.11 | EPS this Y | -2936.76% | Inst Trans | 9.45% | Short Ratio | 10.35 | Perf Half Y | -21.6% |
| Sales | 0.03B | P/B | 4.72 | EPS next 5Y | - | ROA | -53.41% | Short Interest | 10.26M | Perf YTD | -17.67% |
| Book/sh | 5.54 | P/C | 5.76 | EPS past 3/5Y | 64.49% 40.5% | ROE | -61.1% | 52W High | -35.03% ($40.22) | Perf Year | -20.82% |
| Cash/sh | 4.54 | P/FCF | - | Sales past 3/5Y | 145.89% - | ROIC | -60.02% | 52W Low | 28.59% ($20.32) | Perf 3Y | 675.37% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -476.63% | Gross Margin | 84.67% | Volatility(W/M) | 5.92% 5.11% | Perf 5Y | 8.2% |
| Dividend TTM | - | EV/Sales | 50.6 | Sales Y/Y TTM | -86.2% | Oper. Margin | -809.69% | ATR (14) | 1.29 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.69 | EPS Q/Q | -131.96% | Profit Margin | -753.6% | RSI (14) | 51.62 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.69 | Sales Q/Q | -32.51% | SMA20 | 4.85% ($24.92) | Beta | 1.37 | Target Price | $46.46 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/10/29 | SMA50 | -5.94% ($27.78) | Rel Volume | 1.34 | Prev Close | $25.46 |
| Employees | 170 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -16.98% 90.7% | SMA200 | -15.65% ($30.98) | Avg Volume(3M) | 0.99M | Price | $26.13 |
| IPO | 2019/6/19 | Option/Short | Yes/Yes | Trades | 10472 | Volume | 1,324,800 | Change | 2.63% |
🧬 This is a US clinical-stage biotech company developing therapeutics for genetic diseases. Using RNA-based technology, it modulates gene expression to develop candidates that target severe genetic disorders such as hereditary epilepsy and other rare genetic diseases, and holds a leading candidate in late-stage clinical development. It is a biotech entering the rare genetic disease market with an RNA-based platform and a differentiated approach.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
Traded more than usual. That is 134% of its average volume.
Next earnings report: October 29
2 days to go.
STOK has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -2936.8% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $6,111. Peers typically go for $1,213.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be +8.2%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 113.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #117 of 594 in the industry
Based on market cap of $2B.
MESO#114 Mesoblast Ltd ADR $2B PER - 
KLRA#115 Kailera Therapeutics Inc $2B PER - 
GENB#116 Generate Biomedicines Inc $2B PER - STOK#117 Stoke Therapeutics Inc $2B PER - 
QURE#118 uniQure NV $2B PER - 
FAQ
What kind of company is STOK?
STOK belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of STOK?
The market cap of STOK is approximately $1.7B, ranking 2,196 within its sector.
What is the 52-week high and low for STOK?
STOK has recorded a 52-week high of $40.22 and a low of $20.32.
